Related Experiment Videos
Selective estrogen receptor modulators: Women's panacea for the next millennium?
C P Spencer1, E P Morris, J M Rymer
1Department of Obstetrics and Gynaecology, St Thomas' Hospital, London, United Kingdom.
American Journal of Obstetrics and Gynecology
|March 17, 1999
Summary
Selective estrogen receptor modulators show promise for postmenopausal women. These agents may improve bone density and lipid profiles while potentially reducing cancer risks, though long-term studies are necessary.
Area of Science:
- Pharmacology
- Women's Health
- Endocrinology
Background:
- Postmenopausal women face risks of osteoporosis, cardiovascular disease, and certain cancers.
- Estrogen plays a role in bone health, lipid metabolism, and reproductive tissues.
Purpose of the Study:
- To review the potential of selective estrogen receptor modulators (SERMs) for postmenopausal women's health.
- To outline the mechanisms of action for SERMs.
Main Methods:
- Literature review of experimental and clinical data on SERMs.
- Analysis of SERM effects on bone, lipids, endometrium, and breast tissue.
Main Results:
- SERMs exhibit tissue-specific agonist/antagonist activity.
- Raloxifene shows short-term bone preservation and improved lipid profiles.
- Potential benefits include reduced fracture and cardiovascular risk, and lower incidence of breast/endometrial neoplasms.
Conclusions:
- SERMs offer theoretical benefits for postmenopausal health.
- Further long-term studies are required to confirm cancer risk reduction with SERMs like raloxifene.